CellVax Therapeutics Announces FDA Clearance of IND Application for FK-PC101, a Novel Personalized Cancer Immunotherapy

ARCADIA, Calif., Jan. 29, 2024 /PRNewswire/ — Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced that its sponsor client, CellVax Therapeutics Inc., received clearance of its Investigational New Drug application (IND) by the U.S….

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks